clarithromycin has been researched along with piperacillin, tazobactam drug combination in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giamarellos-Bourboulis, EJ; Karagianni, V; Liakou, P; Menenakos, E; Sabracos, L; Spyridaki, A; Tsaganos, T; Tsovolou, EC; Tzepi, IM; Zografos, G | 1 |
| Akyüz, S; Aşker, S; Baran, Aİ; Ekin, S; Özgökçe, M; Sünnetçioğlu, A; Turgut, E; Üney, İ; Yildiz, H | 1 |
2 other study(ies) available for clarithromycin and piperacillin, tazobactam drug combination
| Article | Year |
|---|---|
Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Apoptosis; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Empyema, Pleural; Humans; Interleukin-6; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleural Effusion; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tumor Necrosis Factor-alpha; U937 Cells | 2014 |
Delftia acidovorans pneumonia with lung cavities formation.
Topics: Anti-Bacterial Agents; Clarithromycin; Delftia acidovorans; Female; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Lung; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Tomography, X-Ray Computed | 2019 |